Clinical trial · Interventional
Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)
ONTAK (Denileukin Diftitox) in Patients With Systemic Mastocytosis
NCT00493129CI-TRIAL-00006231completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Primary Objective: 1\. To assess the response rate of ONTAK in Systemic Mastocytosis (SM) patients. Secondary Objectives: 1. To assess the safety of ONTAK in SM patients. 2. To evaluate the time to progression and duration of response following treatment with ONTAK.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Systemic Mastocytosis | Systemic Mastocytosis | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ontak (Denileukin Diftitox) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Ontak
- description
- Ontak administered intravenously on Days 1-5 at the dose of 9 µg/kg/day, with a rest period from Days 6-21.
- interventionNames
- Drug: Ontak (Denileukin Diftitox)
Primary outcomes (1)
- measure
- Objective Response Rate
- timeFrame
- 3 months
- description
- Bone marrow samples used to look at response to therapy collected every 3 months until disease progression or different therapy started. Clinical efficacy assessed as objective response (major and partial response) for responding patients analyzed by the Kaplan-Meier method.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with SM, including mast cell leukemia (MCL). * ECOG Performance Status (PS) 0-3 * Adequate renal function (indicated by serum creatinine \</= 2.5 mg/dL); adequate hepatic function (indicated by ALT \</= 3 \* upper limit of normal; total bilirubin \</= 3 \* upper limit of normal; and albumin \>/= 2.8 g/dL). * Provide written informed consent. * Female patients of childbearing potential must have a negative pregnancy test within 14 days prior to first dose of study drug, and must agree to use an effective means of contraception following the pregnancy test, throughout the study and for at least three weeks after their last treatment on protocol. Exclusion Criteria: * History of hypersensitivity to diphtheria toxin. * Active cardiovascular disease as defined by New York Heart Association (NYHA) Class III-IV categorization. * Serious intercurrent medical illnesses or active infections requiring parenteral antibiotics that would interfere with the ability of the patient to carry out the treatment program. * Concurrent malignancy (other than resected basal or squamous cell skin cancers or in-situ cervical cancer). Unless, patient has SM-associated clonal hematologic disease that does not require therapy, as judged by treating physician and approved by principal investigator. * Female patients who are pregnant or breastfeeding. * No chemotherapy, radiotherapy, immunotherapy, hormonal anticancer therapy, or experimental medications (including approved drugs tested in an investigational setting) may be administered while a patient is a participant in this protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.